OpenBilldrug price receipt

NADAC week of 2026-10-14

ABACAVIR-LAMIVUDINE 600-300 MG

For 30 tablets

Pharmacies pay

$44.51 filed

30 × $1.48365 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: The Part D file flags this drug’s average spending per dosage unit as an outlier, so OpenBill does not use it as a reference price. Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.

The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$56.19 estimated

$44.51 + $6.68 (15%) + $5.00 fee per fill = $56.19

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ABACAVIR-LAMIVUDINE 600-300 MG is how the CMS NADAC file names this product. The FDA NDC Directory lists it as abacavir and lamivudine.

FDA gives its dosage form as tablet, film coated and its route as oral.

FDA lists 4 labelers (the companies named on the label) for its NDCs, among them Camber Pharmaceuticals, Inc., Laurus Labs Limited and Aurobindo Pharma Limited.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 4 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $44.51 for 30 tablets (30 × $1.48365 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

All 4 NDCs

Compared with its class

The middle of its 4 NDCs’ NADAC prices is $1.48365 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 20 have a higher middle NADAC price and 8 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 20 have a higher middle NADAC price and 8 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Its pharmacologic classes

Related in the same class

More